Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 15/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 6/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147779 | 0.89 | ESR2 (0.54) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL24961822 | 0.89 | NPC1 (0.56) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL900534 | 0.84 | SLC18A3 (0.50) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL3453587 | 0.84 | ESR2 (0.46) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL11196166 | 0.84 | ESR2 (0.77) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL1986271 | 0.84 | ESR2 (0.81) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL5284 | 0.84 | SLC18A3 (0.50) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL2051518 | 0.84 | ESR2 (0.46) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL21556845 | 0.84 | ESR2 (0.46) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL15260520 | 0.82 | HDAC8 (0.52) | ESR2SLC18A3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-1858837-B1 | PROCESS FOR THE PRODUCTION OF 2-(2-AMINOPHENYL)-BICYCLOPROPANE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-16 | — | — | EP | disclosed |
| US-7803827-B2 | 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents; 1-(aminosulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(3,4-dimethylphenyl)-2-imidazolidinone | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-7514584-B2 | Process for the production of 2(2-aminophenyl)-bicylopropane derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7504517-B2 | Kv1.5 potassium channel inhibitors | WYETH (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080161610-A1 | Process For the Production of 2(2-Aminophenyl)-Bicylopropane Derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1858837-A1 | PROCESS FOR THE PRODUCTION OF 2-(2-AMINOPHENYL)-BICYCLOPROPANE DERIVATIVES | Syngeta Participations AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006087223-A1 | PROCESS FOR THE PRODUCTION OF 2- (2-AMINOPHENYL)-BICYCLOPROPANE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006087222-A1 | PROCESS FOR THE PRODUCTION OF NITROBENZOLES | SYNGENTA PARTICIPATIONS AG (CH) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006087221-A1 | PROCESS FOR THE PRODUCTION OF NITROBENZOLES | SYNGENTA PARTICIPATIONS AG (CH) | 2006-08-24 | — | — | WO | disclosed |
| EP-1101756-B1 | Aminopyrrolidine derivatives, processes for their preparation and pharmaceutical compositions comprising them | SERVIER LAB (FR) | 2003-03-19 | — | — | EP | disclosed |
| US-6300366-B1 | FOR THERAPY OF CARDIOVASCULAR DISEASES, ESPECIALLY ARTERIAL HYPERTENSION, ARRHYTHMIA | ADIR ET COMPAGNIE (FR) | 2001-10-09 | — | — | US | disclosed |
| EP-1101756-A1 | Aminopyrrolidine derivatives, processes for their preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | ESR2 4484/4885POLB 4818/4885ESR1 4782/4885 |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNA5, KCNH1, KCNK5 | ESR2 4173/4885POLB 4267/4885ESR1 4782/4885 |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | ESR2 4484/4885POLB 4818/4885ESR1 4782/4885 |
| US-20080161610-A1 | Process For the Production of 2(2-Aminophenyl)-Bicylopropane Derivatives | CYP1B1, CYP4B1, MAOB | ESR2 3052/4885POLB 287/4885ESR1 4668/4885 |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | ESR2 1609/4885POLB 3869/4885ESR1 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.